معرفی
Kyle Matchett is a Senior Lecturer at the School of Medicine, Ulster University, with expertise spanning breast cancer research, acute myeloid leukaemia (AML) therapeutics, and epigenetics. His work focuses on hormone signalling, DNA damage mechanisms, and drug discovery, contributing to the UN Sustainable Development Goals in health and well-being.
Education:
- PhD in Molecular Biology (2010) – Queen’s University Belfast
- PGCHET (Postgraduate Certificate in Higher Education Teaching) – 2014
Research Interests:
- Investigating SEPT9 splice variants in ovarian cancer and estrogen metabolism in BRCA1-deficient breast cells.
- Role of erythropoietin (EPO) in breast cancer progression and development of novel EPO receptor antibodies.
- Epigenetic drug combinations for AML, including albendazole repurposing and venetoclax synergy.
Scientific Awards:
- Collaborative Award for Teaching Excellence (CATE) – 2024
- Distinguished Collaborative Education Excellence Fellowship – 2023
- Early Career Research Excellence Award – 2019
- Professor John Fitzpatrick Prize (IACR) – for DNA damage research
Advising & Collaborations: Supervised PhD researchers Sophie Carlin and Ciara Angeli Juan. Collaborated with institutions in Madrid, Innsbruck, Tel-Aviv, Vienna, Munich, Zurich, and industrial partners like Aldevron (Germany).
۰مقاله منتشرشده
